

EXPRESS MAIL LABEL NO. EL 976 543 868 US

Date Mailed: November 3, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents PO Box 1450 Alexandria, Virginia 22313-1450

Sir:

Listed below or on an attached Supplemental Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form Supplemental PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

⊠ apply):		statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that								
		(1)	It is being filed within 3 month than a continued prosecution OR	within 3 months of the application filing date and is other d prosecution application under § 1.53(d)						
		(2) It is being filed within 3 months of entry of a national stage OR								
		(3)		il date of the first Office Action on the merits						
	\boxtimes	(4)		iling of a first Office Action after the filing of a ation under § 1.114.						
	beyond of the r mailing	F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months d the filing date of a national application; (2) three months beyond the date of entry national stage as set forth in §1.491 in an international application; or (3) the date of a first Office action on the merits, but before the mailing date of the of a final office action under §1.113 or a notice of allowance under §1.311, then:								
		a certif	ication as specified in §1.97(e) is provided below; or						
				(p) is authorized below, enclosed, or apers filed together with this statement.						
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:									
	A.	a certif	fication as specified in §1.97(e) is completed below; and						
	B.	a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and								
	C.	a fee o	of \$130.00 as set forth in §1.17 and with the payment of other p	7(i)(1) is authorized below, enclosed, or apers filed together with this statement.						
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0.00 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. <u>08-1641 (Attorney's Docket No. 39780-1618P2C33</u> .									
				Respectfully submitted,						
Dated:	Noven	nber 3,	2004	By: Leslie A. Mooi (Reg. No. 37,047)						
HELLER EHRMAN WHITE & McAULIFFE LLP 275 Middlefield Road Menlo Park, CA 94025-3506 (650) 324-7000 Customer No. 35489										

PTO/SB/08 (2/92) Sheet 1 of 1

- (SUPPLE	MENTAL FO	ORM PTO-1449	Attorney's Docket No. 39780-16	18 P2C33	Applica	tion Seria	l No. 09/904,	766					
INFORMATION DISCLOSURE STATEMEN AND CHAPTER				Av	Avi ASHKENAZI, et al.									
				Filing Date: July 12, 2001		Group Art Unit: 1646								
	(use set	veral sheets	if necessary)											
				U.S. PATENT DOCUMENTS										
Examiner	Ref.	Date	Document No.	Name	Cla	ss S	Subclass	Filing Date (if appropriate)						
Initials	No.													
	1.													
FOREIGN PATENT DOCUMENTS														
Examiner	Ref.	Date	Document No.	Name	Cla	ss Sı	Subclass	Translation						
Initials	No.							YES	NO					
	2.													
				OTHER DOCUMENTS			• .							
			(includin	g author, title, date, pertinent pages, e	tc.)									
Examiner	Ref.	Title												
Initials	No.													
3. Hyman, Elizabeth et al., "Impact of DNA Amplification on Gene Expression Patterns in Breast Research, 62: 6240-6245, (2002).														
	4.	Ørntoftt§, Torben F. et al., "Genome-Wide Study of Gene Copy Numbers, Transcripts, and Protein Levels in Pairs of Non-Invasive and Invasive Human Transitional Cell Carcinomas," Molecular & Cellular Proteomics 1.1, 37-45 (2001).												
	5.	Pollack, Jonathan et al., "Microarray Analysis Reveals a Major Direct Role of DNA Copy Number Alteration in the Transcriptional Program of Human Breast Tumors," PNAS, 99:(20) 12963-12968 (2002).												
	<u> </u>													
,	6.													
	7.													
	8.													
	9. 10.	-												
	11.													
	12.													
	13.													
	14.		-											
	15.													
	16.								•					
	17.													
	18.													
	19.													
	20.		-											
	21.													
	22.													
	22	 												

EXAMINER: DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

*If an asterisk is placed beside the reference number, a copy is not provided because the reference was previously cited by or submitted to the PTO in a prior application that is identical in the statement and relied upon for an earlier filing date under 35 U.S.C. §120. 37 C.F.R. §1.98 (d).

SV 2076773 v1